NCT05402722 is a Phase 2 clinical trial of Eribulin in TNBC - Triple-Negative Breast Cancer, sponsored by Beijing 302 Hospital.

Who is sponsoring NCT05402722?

NCT05402722 is sponsored by Beijing 302 Hospital.

What drugs are being tested in NCT05402722?

Interventions in NCT05402722: Eribulin, anti-PD-1 antibody.

What condition does NCT05402722 study?

NCT05402722 studies TNBC - Triple-Negative Breast Cancer.

Is NCT05402722 still recruiting?

NCT05402722 is currently status unknown. Last updated 2 June 2022.

Last reviewed 2022-06-02 · How we verify

NCT05402722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer

Status unknown Phase 2 Last updated 2 June 2022

What this trial tests

Phase 2 trial testing Eribulin in TNBC - Triple-Negative Breast Cancer in 30 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2022

30 June 2023

Quick facts

Lead sponsor	Beijing 302 Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2022
Primary completion	31 December 2022
Estimated completion	30 June 2023
Sites	1 location across China

Drugs / interventions tested

Eribulin (ERIBULIN) — full drug profile →
anti-PD-1 antibody — full drug profile →

Conditions studied

TNBC - Triple-Negative Breast Cancer — all drugs for TNBC - Triple-Negative Breast Cancer →

Sponsor

Beijing 302 Hospital

Who can join

Adults 18 to 75, female only, with TNBC - Triple-Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy.
Godiyal Y, Maheshwari D, Taniguchi H, Zinzuwadia SS, et al · · 2024 · cited 21× · PMID 39690423 · DOI 10.1186/s40779-024-00586-9
Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y
Role of cancer stem cell ecosystem on breast cancer metastasis and related mouse models.
Peng X, Dong H, Zhang L, Liu S. · · 2024 · cited 4× · PMID 38682432 · DOI 10.24272/j.issn.2095-8137.2023.411

Verify or expand the search:

Other trials of Eribulin

Trials testing the same drug.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07461454 — YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT06957431 — Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma · Phase 1 · recruiting
NCT06942234 — Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06102824 — Organoid-based Functional Precision Therapy for Advanced Breast Cancer · Phase 2 · recruiting

Other recruiting trials for TNBC - Triple-Negative Breast Cancer

Currently open trials in the same condition.

NCT07351487 — Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) · Phase 2 · recruiting
NCT06637306 — Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer · EARLY_PHASE1 · recruiting
NCT07046455 — Trop-2 Targeted PET Probes in Advanced TNBC · NA · recruiting
NCT06627712 — SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC · Phase 3 · recruiting
NCT06534762 — Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study · Phase 2 · recruiting

Other Beijing 302 Hospital trials

Trials by the same sponsor.

NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05402722 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
Last refreshed: 2 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05402722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing